Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2003
10/09/2003WO2003082787A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082360A1 Drug delivery particle
10/09/2003WO2003082345A1 Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith
10/09/2003WO2003082344A1 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like
10/09/2003WO2003082343A1 Drugs for treating liver diseases with the use of hollow protein nanoparticles
10/09/2003WO2003082342A1 Application of kiaa0172 gene to treatment and diagnosis of diseases and drug discovery
10/09/2003WO2003082337A1 Combination comprising a cdk inhibitor and doxorubicin
10/09/2003WO2003082332A1 Remedy for glioblastoma
10/09/2003WO2003082330A1 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
10/09/2003WO2003082324A1 Prevention and treatment of mycoplasma-associated diseases
10/09/2003WO2003082323A1 A composition and method for killing of tumours
10/09/2003WO2003082322A1 A method of modulating cellular activity
10/09/2003WO2003082312A1 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
10/09/2003WO2003082308A1 Drugs including anticancer agents and immunopotentiators and health foods and drinks
10/09/2003WO2003082290A1 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
10/09/2003WO2003082288A1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
10/09/2003WO2003082280A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082277A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors
10/09/2003WO2003082274A1 Angiogenesis inhibitors
10/09/2003WO2003082273A1 Solubilization of weak bases
10/09/2003WO2003082272A1 Substituted benzazoles and use thereof as raf kinase inhibitors
10/09/2003WO2003082271A2 Indole derivatives having anti-angiogenetic activity
10/09/2003WO2003082268A2 Hemiasterlin derivatives and uses thereof in the treatment of cancer
10/09/2003WO2003082267A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
10/09/2003WO2003082266A1 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
10/09/2003WO2003082245A1 Methods of using lamellar bodies for therapeutic purposes
10/09/2003WO2003082212A2 Method for treating cancer in humans
10/09/2003WO2003082200A2 Potent oncolytic herpes simplex virus for cancer therapy
10/09/2003WO2003082189A2 Method for producing pseudo islets
10/09/2003WO2003082186A2 Use of benzimidazole analogs in the treatment of cell proliferation
10/09/2003WO2003052058A3 Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
10/09/2003WO2003049804A3 Treatment of genitourinary tract disorders
10/09/2003WO2003049667A3 The method of treating cancer
10/09/2003WO2003045405A3 Lactic acid bacteria and their use for treating and preventing cancer
10/09/2003WO2003045328A3 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
10/09/2003WO2003040170A3 Antibodies to cd40
10/09/2003WO2003028661A3 Adjuvanted meningococcus compositions
10/09/2003WO2003024465A3 Use of extracts of the genus cimicifuga as organoselective medicines
10/09/2003WO2003020750A3 Antigen mimotopes and vaccine against cancers
10/09/2003WO2003016528A3 Oligonucleotide compositions and their use to induce apoptosis
10/09/2003WO2003013534A3 Methods for the treatment of cancer with irinotecan based on cyp3a5
10/09/2003WO2003013533A3 Methods for improved treatment of cancer with irinotecan based on mrp1
10/09/2003WO2003007889A3 Therapeutic agents comprising pro-apoptotic proteins
10/09/2003WO2002102828A3 Chimeric flavivirus vectors
10/09/2003WO2002083627A3 Ligands des integrins avss6
10/09/2003WO2002078682A3 Estrogen replacement therapy
10/09/2003WO2002077017A3 Medical uses of intercellular communication facilitating compounds
10/09/2003WO2002069947A3 Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
10/09/2003WO2002067928A3 Metronomic dosing of taxanes for inhibiting tumor growth
10/09/2003WO2002060955A3 Modified antibodies and methods of use
10/09/2003WO2002060375A3 Diphenyl ether derivatives and their uses as heparanase inhibitors
10/09/2003WO2002056905A3 Molecular antigen array
10/09/2003WO2002055063A3 Fumaric acid amides
10/09/2003WO2002033099A3 Human kinases
10/09/2003WO2002030433A3 Use of stem cells and cd6-depleted stem cells for inducing tolerance of allogenic transplants and/or for treating leukaemia
10/09/2003WO2002010382A3 Trp8, trp9 and trp10, markers for cancer
10/09/2003WO2002009686A3 Cdc25 phosphatase inhibitors
10/09/2003WO2001085917A3 A device
10/09/2003US20030191322 Synthetic pathway from reacting chemical intermediates 4-carboxy oxazoline with a formyl amide, decarboxylation, hydroxylation, decyclization, lactamization, saponification; proteasome inhibitors, antiinflammatory, antitumor agents
10/09/2003US20030191308 Quinazoline compounds
10/09/2003US20030191300 Antisense modulation of bcl-x expression
10/09/2003US20030191285 Novel g protein-coupled receptor proteins and dnas thereof
10/09/2003US20030191181 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
10/09/2003US20030191180 Pharmaceutical compositions
10/09/2003US20030191178 Therapy for vision defects; hypotensive agents; respiratory system disorders
10/09/2003US20030191175 Indole sPLA2 inhibitors
10/09/2003US20030191170 Central nervous system disorders; antiallergens; respiratory system disorders
10/09/2003US20030191167 Autoimmune disease, antiarthritic agents, antiallergens, anticancer agents
10/09/2003US20030191164 Propane-1,3-dione derivatives
10/09/2003US20030191163 Substituted cyclic amine metalloprotease inhibitors
10/09/2003US20030191157 Injections
10/09/2003US20030191155 Triazole derivatives
10/09/2003US20030191148 Macrolides
10/09/2003US20030191134 Central nervous system disorders; vision defects; antiproliferative agents
10/09/2003US20030191129 Antitumor agents
10/09/2003US20030191114 Binding to ligand; induce signals
10/09/2003US20030191111 Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
10/09/2003US20030191104 Therapy for carbohydrate metabolism disorders
10/09/2003US20030191103 Hormone replacement therapy
10/09/2003US20030191099 Antiestrogen compound
10/09/2003US20030191098 Synergistic mixture of thalidomide antiinflammatory agnets
10/09/2003US20030191097 Hormone replacement therapy
10/09/2003US20030191093 Pharmaceutical compositions comprising active vitamin D compounds
10/09/2003US20030191092 MMP inhibitors
10/09/2003US20030191086 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
10/09/2003US20030191082 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
10/09/2003US20030191079 Methods for treating and preventing infectious disease
10/09/2003US20030191074 Antibody therapy; immobilization
10/09/2003US20030191065 Insulin-like growth factor; genetic engineering; central nervous system disorders
10/09/2003US20030191052 Infection therapy; binding of mannan lecithin to protein
10/09/2003US20030190739 Tankyrase2 materials and methods
10/09/2003US20030190733 Desaturase genes and uses thereof
10/09/2003US20030190708 Novel hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use
10/09/2003US20030190707 17 human secreted proteins
10/09/2003US20030190687 Interacts with human DR5 to produce agonistic or antagonistic effects including inhibition of cell proliferation and apoptosis; used to treat apoptosis-related disease and unregulated cell growth
10/09/2003US20030190686 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmacetical compositions containing such compounds
10/09/2003US20030190685 Bind to Tumor Necrosis Factor(TNF)-Related Apoptosis Inducing Ligand (TRAIL) receptors ; used in the prevention and treatment of cancers and other proliferative disorders
10/09/2003US20030190659 Oligomers that hybridize to Inhibition of Apoptosis (IAP) polynucleotides and methods for using them to enhance apoptosis and treat proliferative diseases
10/09/2003US20030190651 Preventing, ameliorating, correcting dysfunctions or diseases such as cancer, peripheral and central nervous system diseases, and chronic obstructive pulmonary disease
10/09/2003US20030190642 Thymus expressed human cytochrome p450(p450tec)
1 ... 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 ... 2211